Nomad Power Solutions (NMAD) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Spero Therapeutics (SPRO) over the past year, losing 14.5% versus a loss of 45.8%. Over five years, NMAD leads with a -77.3% price change compared with -93.1% for SPRO. Nomad Power Solutions is the larger company by market cap ($68.8 million vs $67.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMAD | SPRO |
|---|---|---|
| Share price | $4.27 | $1.16 |
| Market cap | $68.75M | $67.26M |
| 1-day change | +0.47% | -1.29% |
| YTD return | +8.14% | -49.79% |
| 1-year return | -14.49% | -45.83% |
| 5-year return | -77.27% | -93.13% |
| P/E ratio (TTM) | — | 8.25 |
| EPS (TTM) | $-1.01 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.38 | $3.08 |
| 52-week low | $2.36 | $1.08 |
| Distance from 52-week high | -49.05% | -62.50% |
| Average volume | 277.61K | 1.20M |
| Shares outstanding | 16.10M | 58.23M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed SPRO by 31.3 percentage points over the past year.
NMAD vs SPRO FAQ
Which is bigger, Nomad Power Solutions or Spero Therapeutics?
Nomad Power Solutions (NMAD) is larger, with a market capitalization of $68.75M compared with $67.26M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, NMAD or SPRO?
NMAD returned -14.49% over the past 12 months, compared with -45.83% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Nomad Power Solutions and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.